Secondary Skin Cancer in a Case with Long-term Voriconazole after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Noriaki Kawano, Shunou Nakamura, Kousuke Mochida, Shuro Yoshida, Takuro Kuriyama, Takashi Nakaike, Tomonori Shimokawa, Taro Tochigi, Kiyoshi Yamashita, Koichi Mashiba, Ikuo Kikuchi, Aina Takarabe, Sayaka Moriguchi, Yasuo Mori, Katsuto Takenaka, Kazuya Shimoda, Hidenobu Ochiai, Masahiro Amano

Research output: Contribution to journalArticlepeer-review

Abstract

Secondary malignancies that develop after allogeneic-hematopoietic stem cell transplantation (allo-HSCT) have become serious issues. A 47-year-old man who developed acute myeloid leukemia in 2009 and subsequently underwent allo-HSCT twice: in 2009 and 2011. In 2015, voriconazole for lung aspergillus was started. In 2018, chronic graft-versus-host disease (GVHD) and multiple actinic keratoses manifested at his head. In 2020, some lesions were diagnosed as squamous cell carcinoma, so voriconazole was withdrawn, and subsequent surgery and radiation led to remission. Long-term administration of voriconazole in addition to allo-HSCT and chronic GVHD may be closely related to secondary skin cancer.

Original languageEnglish
Pages (from-to)2771-2774
Number of pages4
JournalInternal Medicine
Volume61
Issue number18
DOIs
Publication statusPublished - 2022
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Secondary Skin Cancer in a Case with Long-term Voriconazole after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this